Factive Gets May User Fee Date For Community Acquired Pneumonia Label Expansion
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA accepts Oscient’s submission as a “complete response” to a Sept. 21 “approvable” letter for the antibiotic.
You may also be interested in...
Oscient Gets Factive Price Reduction From LG Life Sciences For European Distribution
Oscient indicates the agreement could help facilitate a European partnership for the antibiotic.
Oscient Gets Factive Price Reduction From LG Life Sciences For European Distribution
Oscient indicates the agreement could help facilitate a European partnership for the antibiotic.
Factive Pneumonia sNDA Needs To Take Five
FDA “approvable” letter for five-day regimen requests data clarification, but no additional trials anticipated.